Allowed Publications
Federal Practitioner
Slot System
Featured Buckets
Featured Buckets Admin

Drug-Disease Interactions in Elders

Article Type
Article
Changed
Display Headline
Drug-Disease Interactions in Elders

Article PDF
022060032_1.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(6)
Publications
Federal Practitioner
Page Number
32
Legacy Keywords
drug-disease interactions, elders, gerontology, adverse drug effects, interactions, patient safety, Geriatric Evaluation and Management trial, GEMdrug-disease interactions, elders, gerontology, adverse drug effects, interactions, patient safety, Geriatric Evaluation and Management trial, GEM
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022060032_1.pdf
Article PDF
022060032_1.pdf

Issue
Federal Practitioner - 22(6)
Issue
Federal Practitioner - 22(6)
Page Number
32
Page Number
32
Publications
Federal Practitioner
Publications
Federal Practitioner
Article Type
Article
Display Headline
Drug-Disease Interactions in Elders
Display Headline
Drug-Disease Interactions in Elders
Legacy Keywords
drug-disease interactions, elders, gerontology, adverse drug effects, interactions, patient safety, Geriatric Evaluation and Management trial, GEMdrug-disease interactions, elders, gerontology, adverse drug effects, interactions, patient safety, Geriatric Evaluation and Management trial, GEM
Legacy Keywords
drug-disease interactions, elders, gerontology, adverse drug effects, interactions, patient safety, Geriatric Evaluation and Management trial, GEMdrug-disease interactions, elders, gerontology, adverse drug effects, interactions, patient safety, Geriatric Evaluation and Management trial, GEM
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Post-PCI Fluvastatin for Diabetics

Article Type
Article
Changed
Display Headline
Post-PCI Fluvastatin for Diabetics

Article PDF
022060032_0.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(6)
Publications
Federal Practitioner
Type 2 Diabetes ICYMI
Topics
Cardiology
Diabetes
Page Number
32
Legacy Keywords
fluvastatin, diabetes, Lescol Intervention Prevention Study, LIPS, long-term statin therapy, percutaneous coronary intervention, PCI, cardiac risksfluvastatin, diabetes, Lescol Intervention Prevention Study, LIPS, long-term statin therapy, percutaneous coronary intervention, PCI, cardiac risks
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022060032_0.pdf
Article PDF
022060032_0.pdf

Issue
Federal Practitioner - 22(6)
Issue
Federal Practitioner - 22(6)
Page Number
32
Page Number
32
Publications
Federal Practitioner
Type 2 Diabetes ICYMI
Publications
Federal Practitioner
Type 2 Diabetes ICYMI
Topics
Cardiology
Diabetes
Article Type
Article
Display Headline
Post-PCI Fluvastatin for Diabetics
Display Headline
Post-PCI Fluvastatin for Diabetics
Legacy Keywords
fluvastatin, diabetes, Lescol Intervention Prevention Study, LIPS, long-term statin therapy, percutaneous coronary intervention, PCI, cardiac risksfluvastatin, diabetes, Lescol Intervention Prevention Study, LIPS, long-term statin therapy, percutaneous coronary intervention, PCI, cardiac risks
Legacy Keywords
fluvastatin, diabetes, Lescol Intervention Prevention Study, LIPS, long-term statin therapy, percutaneous coronary intervention, PCI, cardiac risksfluvastatin, diabetes, Lescol Intervention Prevention Study, LIPS, long-term statin therapy, percutaneous coronary intervention, PCI, cardiac risks
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Brain Death After Valproic Acid Overdose

Article Type
Article
Changed
Display Headline
Brain Death After Valproic Acid Overdose

Article PDF
022060032.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(6)
Publications
Federal Practitioner
Topics
Neurology
Page Number
32
Legacy Keywords
brain death, valproic acid, overdose, venlafaxine, risperidone, cerebral edema, antiseizure drugs, adverse drug effects, interactionsbrain death, valproic acid, overdose, venlafaxine, risperidone, cerebral edema, antiseizure drugs, adverse drug effects, interactions
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022060032.pdf
Article PDF
022060032.pdf

Issue
Federal Practitioner - 22(6)
Issue
Federal Practitioner - 22(6)
Page Number
32
Page Number
32
Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Neurology
Article Type
Article
Display Headline
Brain Death After Valproic Acid Overdose
Display Headline
Brain Death After Valproic Acid Overdose
Legacy Keywords
brain death, valproic acid, overdose, venlafaxine, risperidone, cerebral edema, antiseizure drugs, adverse drug effects, interactionsbrain death, valproic acid, overdose, venlafaxine, risperidone, cerebral edema, antiseizure drugs, adverse drug effects, interactions
Legacy Keywords
brain death, valproic acid, overdose, venlafaxine, risperidone, cerebral edema, antiseizure drugs, adverse drug effects, interactionsbrain death, valproic acid, overdose, venlafaxine, risperidone, cerebral edema, antiseizure drugs, adverse drug effects, interactions
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Imatinib for Kaposi Sarcoma: A Mixed Blessing

Article Type
Article
Changed
Display Headline
Imatinib for Kaposi Sarcoma: A Mixed Blessing

Article PDF
022050063_0.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(5)
Publications
Federal Practitioner
Topics
HIV
Page Number
63
Legacy Keywords
AIDS, HIV, imatinib mesylate, kaposi sarcoma, dermatologyAIDS, HIV, imatinib mesylate, kaposi sarcoma, dermatology
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022050063_0.pdf
Article PDF
022050063_0.pdf

Issue
Federal Practitioner - 22(5)
Issue
Federal Practitioner - 22(5)
Page Number
63
Page Number
63
Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
HIV
Article Type
Article
Display Headline
Imatinib for Kaposi Sarcoma: A Mixed Blessing
Display Headline
Imatinib for Kaposi Sarcoma: A Mixed Blessing
Legacy Keywords
AIDS, HIV, imatinib mesylate, kaposi sarcoma, dermatologyAIDS, HIV, imatinib mesylate, kaposi sarcoma, dermatology
Legacy Keywords
AIDS, HIV, imatinib mesylate, kaposi sarcoma, dermatologyAIDS, HIV, imatinib mesylate, kaposi sarcoma, dermatology
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Dual vs. Single Blockade in Diabetic Hypertension

Article Type
Article
Changed
Display Headline
Dual vs. Single Blockade in Diabetic Hypertension

Article PDF
022050063.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(5)
Publications
Federal Practitioner
Page Number
63
Legacy Keywords
diabetic hypertension, angiotensin converting enzyme inhibitor, ACE inhibitor, angiotensin II receptor blocker, candesartan, lisinopril 20, lisinopril 40, anithypertensives, high blood pressure, hypertensiondiabetic hypertension, angiotensin converting enzyme inhibitor, ACE inhibitor, angiotensin II receptor blocker, candesartan, lisinopril 20, lisinopril 40, anithypertensives, high blood pressure, hypertension
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022050063.pdf
Article PDF
022050063.pdf

Issue
Federal Practitioner - 22(5)
Issue
Federal Practitioner - 22(5)
Page Number
63
Page Number
63
Publications
Federal Practitioner
Publications
Federal Practitioner
Article Type
Article
Display Headline
Dual vs. Single Blockade in Diabetic Hypertension
Display Headline
Dual vs. Single Blockade in Diabetic Hypertension
Legacy Keywords
diabetic hypertension, angiotensin converting enzyme inhibitor, ACE inhibitor, angiotensin II receptor blocker, candesartan, lisinopril 20, lisinopril 40, anithypertensives, high blood pressure, hypertensiondiabetic hypertension, angiotensin converting enzyme inhibitor, ACE inhibitor, angiotensin II receptor blocker, candesartan, lisinopril 20, lisinopril 40, anithypertensives, high blood pressure, hypertension
Legacy Keywords
diabetic hypertension, angiotensin converting enzyme inhibitor, ACE inhibitor, angiotensin II receptor blocker, candesartan, lisinopril 20, lisinopril 40, anithypertensives, high blood pressure, hypertensiondiabetic hypertension, angiotensin converting enzyme inhibitor, ACE inhibitor, angiotensin II receptor blocker, candesartan, lisinopril 20, lisinopril 40, anithypertensives, high blood pressure, hypertension
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Adalimumab for Resistant Crohn Disease

Article Type
Article
Changed
Display Headline
Adalimumab for Resistant Crohn Disease

Article PDF
022040024_1.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(4)
Publications
Federal Practitioner
Page Number
24
Legacy Keywords
gastroenterology, adalimumab, Crohn's disease, infliximab, tumor necrosis factor alphagastroenterology, adalimumab, Crohn's disease, infliximab, tumor necrosis factor alpha
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022040024_1.pdf
Article PDF
022040024_1.pdf

Issue
Federal Practitioner - 22(4)
Issue
Federal Practitioner - 22(4)
Page Number
24
Page Number
24
Publications
Federal Practitioner
Publications
Federal Practitioner
Article Type
Article
Display Headline
Adalimumab for Resistant Crohn Disease
Display Headline
Adalimumab for Resistant Crohn Disease
Legacy Keywords
gastroenterology, adalimumab, Crohn's disease, infliximab, tumor necrosis factor alphagastroenterology, adalimumab, Crohn's disease, infliximab, tumor necrosis factor alpha
Legacy Keywords
gastroenterology, adalimumab, Crohn's disease, infliximab, tumor necrosis factor alphagastroenterology, adalimumab, Crohn's disease, infliximab, tumor necrosis factor alpha
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Pioglitazone and Edema

Article Type
Article
Changed
Display Headline
Pioglitazone and Edema

Article PDF
022040024_0.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(4)
Publications
Federal Practitioner
Page Number
24
Legacy Keywords
pioglitazone, pulmonary edema, PE, left ventricular dysfunction, normal, left ventricular function, heart failure, thiazolidinediones, diabetes, hypertension, fluid retentionpioglitazone, pulmonary edema, PE, left ventricular dysfunction, normal, left ventricular function, heart failure, thiazolidinediones, diabetes, hypertension, fluid retention
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022040024_0.pdf
Article PDF
022040024_0.pdf

Issue
Federal Practitioner - 22(4)
Issue
Federal Practitioner - 22(4)
Page Number
24
Page Number
24
Publications
Federal Practitioner
Publications
Federal Practitioner
Article Type
Article
Display Headline
Pioglitazone and Edema
Display Headline
Pioglitazone and Edema
Legacy Keywords
pioglitazone, pulmonary edema, PE, left ventricular dysfunction, normal, left ventricular function, heart failure, thiazolidinediones, diabetes, hypertension, fluid retentionpioglitazone, pulmonary edema, PE, left ventricular dysfunction, normal, left ventricular function, heart failure, thiazolidinediones, diabetes, hypertension, fluid retention
Legacy Keywords
pioglitazone, pulmonary edema, PE, left ventricular dysfunction, normal, left ventricular function, heart failure, thiazolidinediones, diabetes, hypertension, fluid retentionpioglitazone, pulmonary edema, PE, left ventricular dysfunction, normal, left ventricular function, heart failure, thiazolidinediones, diabetes, hypertension, fluid retention
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Does NSAID Use Affect FOB Results?

Article Type
Article
Changed
Display Headline
Does NSAID Use Affect FOB Results?

Article PDF
022040024.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(4)
Publications
Federal Practitioner
Page Number
24
Legacy Keywords
NSAID, nonsteroidal anti-inflammatory drugs, fecal occult blood test, FOB test, colonoscopy, aspirinNSAID, nonsteroidal anti-inflammatory drugs, fecal occult blood test, FOB test, colonoscopy, aspirin
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022040024.pdf
Article PDF
022040024.pdf

Issue
Federal Practitioner - 22(4)
Issue
Federal Practitioner - 22(4)
Page Number
24
Page Number
24
Publications
Federal Practitioner
Publications
Federal Practitioner
Article Type
Article
Display Headline
Does NSAID Use Affect FOB Results?
Display Headline
Does NSAID Use Affect FOB Results?
Legacy Keywords
NSAID, nonsteroidal anti-inflammatory drugs, fecal occult blood test, FOB test, colonoscopy, aspirinNSAID, nonsteroidal anti-inflammatory drugs, fecal occult blood test, FOB test, colonoscopy, aspirin
Legacy Keywords
NSAID, nonsteroidal anti-inflammatory drugs, fecal occult blood test, FOB test, colonoscopy, aspirinNSAID, nonsteroidal anti-inflammatory drugs, fecal occult blood test, FOB test, colonoscopy, aspirin
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Adrenal Insufficiency and Vasopressor-Resistant Hypotension in Critical Illness

Article Type
Article
Changed
Display Headline
Adrenal Insufficiency and Vasopressor-Resistant Hypotension in Critical Illness
Author(s)
Baylor PA

Article PDF
022030060.pdf
Author and Disclosure Information

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Albert Einstein College of Medicine and Quadrant HealthCom Inc. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he or she actually spent in the activity.

Peter A. Baylor, MD

Dr. Baylor is the associate chief of the pulmonary section at the VA Central California Health Care System, Fresno and an assistant clinical professor of medicine at the Fresno Medical Education Program of the University of California, San Fransisco.

Issue
Federal Practitioner - 22(3)
Publications
Federal Practitioner
Page Number
60
Legacy Keywords
adrenal insufficiency, kidney disease, critical illness, vasopressor-resistant hypotension, hypotensionadrenal insufficiency, kidney disease, critical illness, vasopressor-resistant hypotension, hypotension
Sections
Pharmacology
Author(s)
Baylor PA
Author(s)
Baylor PA
Author and Disclosure Information

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Albert Einstein College of Medicine and Quadrant HealthCom Inc. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he or she actually spent in the activity.

Peter A. Baylor, MD

Dr. Baylor is the associate chief of the pulmonary section at the VA Central California Health Care System, Fresno and an assistant clinical professor of medicine at the Fresno Medical Education Program of the University of California, San Fransisco.

Author and Disclosure Information

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Albert Einstein College of Medicine and Quadrant HealthCom Inc. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he or she actually spent in the activity.

Peter A. Baylor, MD

Dr. Baylor is the associate chief of the pulmonary section at the VA Central California Health Care System, Fresno and an assistant clinical professor of medicine at the Fresno Medical Education Program of the University of California, San Fransisco.

Article PDF
022030060.pdf
Article PDF
022030060.pdf

Issue
Federal Practitioner - 22(3)
Issue
Federal Practitioner - 22(3)
Page Number
60
Page Number
60
Publications
Federal Practitioner
Publications
Federal Practitioner
Article Type
Article
Display Headline
Adrenal Insufficiency and Vasopressor-Resistant Hypotension in Critical Illness
Display Headline
Adrenal Insufficiency and Vasopressor-Resistant Hypotension in Critical Illness
Legacy Keywords
adrenal insufficiency, kidney disease, critical illness, vasopressor-resistant hypotension, hypotensionadrenal insufficiency, kidney disease, critical illness, vasopressor-resistant hypotension, hypotension
Legacy Keywords
adrenal insufficiency, kidney disease, critical illness, vasopressor-resistant hypotension, hypotensionadrenal insufficiency, kidney disease, critical illness, vasopressor-resistant hypotension, hypotension
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

New Warning for Atomoxetine

Article Type
Article
Changed
Display Headline
New Warning for Atomoxetine

Article PDF
022030047_3.pdf
Author and Disclosure Information

Issue
Federal Practitioner - 22(3)
Publications
Federal Practitioner
Topics
Neurology
Page Number
48
Legacy Keywords
atomoxetine hydrochloride, liver injury, adverse drug effects, ADHD, attention deficit hyperactivity disorderatomoxetine hydrochloride, liver injury, adverse drug effects, ADHD, attention deficit hyperactivity disorder
Sections
Pharmacology
Author and Disclosure Information

Author and Disclosure Information

Article PDF
022030047_3.pdf
Article PDF
022030047_3.pdf

Issue
Federal Practitioner - 22(3)
Issue
Federal Practitioner - 22(3)
Page Number
48
Page Number
48
Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Neurology
Article Type
Article
Display Headline
New Warning for Atomoxetine
Display Headline
New Warning for Atomoxetine
Legacy Keywords
atomoxetine hydrochloride, liver injury, adverse drug effects, ADHD, attention deficit hyperactivity disorderatomoxetine hydrochloride, liver injury, adverse drug effects, ADHD, attention deficit hyperactivity disorder
Legacy Keywords
atomoxetine hydrochloride, liver injury, adverse drug effects, ADHD, attention deficit hyperactivity disorderatomoxetine hydrochloride, liver injury, adverse drug effects, ADHD, attention deficit hyperactivity disorder
Sections
Pharmacology
Article Source

PURLs Copyright

Inside the Article

Article PDF Media
Subscribe to Pharmacology